摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one | 1240483-13-9

中文名称
——
中文别名
——
英文名称
(3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one
英文别名
——
(3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one化学式
CAS
1240483-13-9
化学式
C24H34O4Si
mdl
——
分子量
414.61
InChiKey
AHUDTPUBARLZSD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    525.3±50.0 °C(Predicted)
  • 密度:
    1.07±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.09
  • 重原子数:
    29.0
  • 可旋转键数:
    7.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    52.6
  • 氢给体数:
    0.0
  • 氢受体数:
    4.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one 以85的产率得到(3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-hydroxy-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one
    参考文献:
    名称:
    PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES
    摘要:
    本发明涉及一种制备前列腺素衍生物的新工艺,特别是前列腺素F2α衍生物,例如比马前列素、拉坦前列素和特罗前列素,以及该工艺的新中间体及其在制备前列腺素衍生物中的应用。
    公开号:
    US20120016136A1
  • 作为产物:
    描述:
    (3aR,4S,5S,6aS)-5-[tert-butyl(dimethyl)silyl]oxy-2-oxo-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-4-carbaldehyde 以93的产率得到(3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one
    参考文献:
    名称:
    NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF
    摘要:
    本发明涉及一种新型的制备具有式(K)的前列腺素化合物的方法,其中R选自以下组中的一种:C1-C7烷基;C7-C17芳基烷基,其中芳基基团未取代或取代有1至3个取代基,所述取代基选自C1-C6烷基,卤素和CF3;以及(CH2)nOR2,其中n为1至3,R2代表未取代或取代有1至3个取代基的C6-C10芳基基团,所述取代基选自C1-C6烷基,卤素和CF3;R1选自OR3和NHR3,其中R3为C1-C6烷基,H;虚线表示双键或单键。本发明还公开了新型中间体。
    公开号:
    US20120209011A1
点击查看最新优质反应信息

文献信息

  • [EN] PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PROSTAGLANDINES DE LA SÉRIE F
    申请人:CAYMAN CHEM CO
    公开号:WO2011046569A1
    公开(公告)日:2011-04-21
    A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.
    一种合成和纯化F系列前列腺素化合物及其合成中间体的方法。这些合成中间体是固体并且可以通过沉淀纯化,因此可以形成高纯度的代表性F系列前列腺素化合物,如拉坦前列素比马前列素前列醇,克罗前列醇和其取代类似物。
  • Process for the preparation of F-series prostaglandins
    申请人:Chambournier Gilles
    公开号:US08901319B2
    公开(公告)日:2014-12-02
    A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.
    一种用于合成和纯化F系列前列腺素化合物及用于制备它们的合成中间体的过程。这些合成中间体是固体,可以通过沉淀纯化,因此可以形成代表性的F系列前列腺素化合物,如拉坦前列素比马前列素前列醇、前列素和其取代类似物,以高度纯净的形式。
  • [EN] NOVEL PROCESSES FOR THE PREPARATION OF PROSTAGLANDIN AMIDES<br/>[FR] NOUVEAU PROCÉDÉ POUR LA PRÉPARATION D'AMIDES DE PROSTAGLANDINES
    申请人:CHINOIN ZRT
    公开号:WO2012164324A1
    公开(公告)日:2012-12-06
    The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, - where in the formula the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at positions 5,6 and 13,14 they may be in cis or in trans orientation, Q stands for a hydroxyl-group and Z stands for a hydroxyl- or oxo-group, R1 and R2 independently represent hydrogen atom or a straight or branched C1-10 alkyl- or aralkyl- group, optionally substituted with -ONO2 group, or an aralkyl- or aryl- group, which contains heteroatom, R3 represents a straight or branched, saturated or unsaturated C4-6 hydrocarbon group, or a C4-10 alkylcycloalkyl- or cycloalkyl- group, or an optionally with alkyl group or halogen atom substituted phenyl-, C7-10 alkylaryl- or hetaryl- group, Y represents (CH2)n group or 0 atom or S atom, and where n=0-3.
    本发明的主题是一种制备通式I的前列腺素酰胺的方法,其中在该式中,用虚线标记的键可以是单键或双键,在位置5,6和13,14处的双键可以是顺式或反式的,Q代表羟基,Z代表羟基或氧基,R1和R2分别代表氢原子或直链或支链C1-10烷基或芳基烷基,可选地取代-ONO2基团,或含有杂原子的芳基烷基或芳基基团,R3代表直链或支链、饱和或不饱和的C4-6烃基,或C4-10烷基环烷基或环烷基基团,或可选地用烷基或卤原子取代的苯基、C7-10烷基芳基基团或杂芳基基团,Y代表(CH2)n基团、0原子或S原子,其中n=0-3。
  • [EN] PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE DÉRIVÉS DE PROSTAGLANDINE
    申请人:SIFAVITOR S R L
    公开号:WO2010097672A1
    公开(公告)日:2010-09-02
    The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use in the preparation of prostaglandin derivatives.Said process comprises: a) reacting compounds of formula (I) with compounds of formula (II) to give compounds of formula (III) b) reducing with an asymmetric reducing agent the oxo group of the side chain of compounds of formula (III) to give compounds of formula (IV)
    本发明涉及一种制备前列腺素生物(特别是前列腺素F2α衍生物,例如比马酯,拉坦前列素和特罗前列素)的新工艺,该工艺的新中间体以及它们在前列腺素生物制备中的应用。该工艺包括:a)将式(I)化合物与式(II)化合物反应,以得到式(III)化合物;b)使用不对称还原剂还原式(III)化合物的侧链羰基,以得到式(IV)化合物。
  • [EN] A NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE PROSTAGLANDINES ET DE LEURS INTERMÉDIAIRES
    申请人:BIOCON LTD
    公开号:WO2011055377A1
    公开(公告)日:2011-05-12
    This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and (CH2)nOR2 wherein n is from 1 to 3 and R2 represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and R1 is selected from OR3 and NHR3 wherein R3 is C1-C6 alkyl, H; and dashed lines represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.
    本发明涉及一种新的制备具有式(K)的前列腺素化合物的过程,其中R选自以下组:C1-C7烷基;C7-C17芳基烷基,其中芳基基团未取代或取代有来自C1-C6烷基,卤素和CF3的一到三个取代基;以及(CH2)nOR2,其中n为1到3,R2代表未取代或取代有来自C1-C6烷基,卤素和 的一到三个取代基的C6-C10芳基基团;而R1选自OR3和NHR3,其中R3为C1-C6烷基,H;虚线表示双键或单键。同时,本发明还揭示了新的中间体。
查看更多